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Abstract 
Natural IgM autoantibodies have been proposed to convey 
protection from autoimmune pathogenesis. Herein, we 
investigated the IgM responses in 396 systemic lupus 
erythematosus (SLE) patients, divided into subgroups based on 
distinct autoantibody profiles. Depressed IgM levels were more 
common in SLE than in matched population controls. 
Strikingly, an autoreactivity profile defined by IgG anti-Ro/La 
was associated with reduced levels of specific natural IgM 
anti-phosphorylcholine (PC) antigens and anti-
malondialdehyde (MDA) modified-protein, as well total IgM, 
while no differences were detected in SLE patients with an 
autoreactivity profile defined by anti-
cardiolipin/b2glycoprotein-I. We also observed an association 
of reduced IgM levels with the HLA-DRB1*03 allelic variant 
amongst SLE patients and controls. Associations of low IgM 
anti-PC with cardiovascular disease were primarily found in 
patients without antiphospholipid antibodies. These studies 
further highlight the clinical relevance of depressed IgM. Our 
results suggest that low IgM levels in SLE patients reflect 
immunological and genetic differences between SLE 
subgroups. 
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Highlights: 
* Low IgM levels are more common in SLE patients than in 
controls  
* Patients with anti-Ro/La autoimmunity often have strikingly 
decreased IgM levels  
* Low IgM was seen for specific IgM anti-PC, anti-MDA, anti-
CWPS, as well as total IgM 
* Low natural IgM may be associated to HLA-DRB1*03 in 
both SLE and controls 
1. Introduction 
Systemic lupus erythematosus (SLE) is an autoimmune disease 
associated with a great diversity of clinical features, complex 
pathogenesis [1, 2], and a central hallmark of distinct types of 
IgG autoantibodies. Almost all SLE patients are at the time of 
diagnosis positive for antinuclear autoantibodies (ANA), an 
umbrella immunofluorescence test that detects nuclear 
specificities, which include disease-specific IgG anti-dsDNA 
antibodies, present in 40-60% of SLE patients. Such IgG lupus 
autoantibodies have been hypothesized to be directly 
pathogenic in SLE through pathways mediated by Fc-receptor 
interaction, TLR activation, and induction of type I interferons 
[3, 4]. Yet, it remains controversial whether all autoantibodies 
are directly pathogenic or represent bystander effects that are 
peripheral to the disease process. Indeed, lupus is associated 
with a number of IgG-autoantibody specificities including anti-
Sm, anti-RNP, anti-C1q, anti-nucleosome, anti-Ro/SSA, anti-
La/SSB and antiphospholipid autoantibodies (i.e. anti-
CL/b2GPI) [1, 2].  
 
Some SLE patients are affected by secondary clinical 
syndromes, i.e. secondary Sjögren’s syndrome (sSS) and 
secondary anti-phospholipid syndrome (sAPS), which display 
distinct clinical features. APS patients suffer from arterial and 
venous thrombotic events and/or pregnancy morbidities [5-7], 
and SS patients have involvement of lachrymal and salivary 
glands [8, 9]. For secondary APS, anti-CL/b2GPI 
autoantibodies are included in the diagnosis [6] while for 
secondary SS the presence of primary SS-associated 
autoantibodies (anti-Ro/La) are not required [9].  
 
The appearance of diverse autoreactivities in SLE patients has 
been suggested to result in part from defects in the homeostatic 
clearance of apoptotic cells leading to exposure to apoptotic 
cell antigens in an inflammatory milieu [10]. Intriguingly, 
natural IgM often recognize epitopes expressed on apoptotic 
cells. These IgM are present already at birth, and are postulated 
to convey beneficial housekeeping properties, which may also 
enhance apoptotic cell clearance [11, 12].  
 
Natural IgM are primarily constitutively produced by 
specialized innate like B-cell subsets, without the need for 
additional immune stimulation. Indeed, in mice up to 80% of 
the circulating IgM molecules are spontaneously produced [13, 
14]. The repertoire of natural IgM, in both mice and humans, is 
biased towards the recognition of oxidation-associated antigen-
specificities, which include epitopes on malondialdehyde 
(MDA) oxidation-modified proteins, and phosphorylcholine 
(PC) in oxidized lipids [15]. PC epitopes are present on 
apoptotic cells, in oxidized low-density lipoprotein, and also on 
the pneumococcal cell wall polysaccharide. Natural IgM anti-
PC may thus have dual roles in both enhancing phagocytic 
clearance of dead cells, and as a first line of defense against 
invasive infections, including to S. pneumoniae.  
 
Importantly, IgM anti-PC antibodies have been shown to be 
directly anti-inflammatory in in vitro assays and in vivo in 
murine models [16-20]. A large number of studies have 
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demonstrated that low levels of IgM anti-PC are associated 
with higher risk of cardiovascular disease both in SLE patients 
and in the general population [21-28]. It can be speculated that 
there is a dynamic balance between these protective IgM and 
disease-associated pathogenic autoreactive IgG in SLE. Hence 
reduced levels of circulating IgM may by itself significantly 
affect SLE pathogenesis. Yet, SLE is an immensely 
heterogeneous disease and there are often great differences 
between patients. We therefore hypothesized that IgM levels 
may differ between subsets of patients with SLE. In the current 
study, we document that there are large variations in the levels 
of total IgM and in specificities of certain natural IgM 
antibodies in SLE subgroups defined by lupus IgG 
autoantibody profiles.  
 
2. Materials and methods 
2.1 Subjects, clinical data, and subgroups 
This cross-sectional study includes 437 consecutive patients 
from the Karolinska SLE cohort enrolled between 2004-2011 
and fulfilling at least four of the 1982 revised classification 
criteria for SLE according to the American College of 
Rheumatology [29]. SLE patients were assigned to subgroups 
based on autoantibody profiles at the time of blood sample 
collection into antiphospholipid (APS)-profile or Sjögren (SS)-
profile (Table 1). The patients assigned to the APS-profile 
group had either two or more IgG/IgA/IgM anti-CL/b2GPI 
positive tests, and/or a lupus anticoagulant (LA) positive test. 
The SS-profile group had to have two or more positive IgG 
anti-Ro52/Ro60/La tests. Notably, clinical diagnosis and 
manifestations were not considered in the subgrouping. We 
focused exclusively on current immunological autoreactivity 
status. The following patients were excluded: patients that 
would fulfill both profile criteria (n=19), patients that did not 
have sufficient serological tests for subgrouping (n=42), and 
patients that had received Rituximab treatment at any time 
point prior to blood sampling (n=40). The remaining SLE 
patients were subgrouped as having another autoantibody 
profile (“other Abs”). Disease activity was measured by the 
SLE disease activity index 2000 (SLEDAI-2K)[30] and SLE 
associated organ damage was assessed by the Systemic Lupus 
International Collaborating Clinics (SLICC)/ACR Damage 
Index [31]. For comparison of distribution between subgroups 
clinical assessment of secondary APS was determined by 
fulfillment of clinical criteria by Miyakis et al. [6] and 
secondary SS by the American European Consensus criteria 
[9]. Atherosclerosis was evaluated with carotid ultrasound 
intima-media thickness (IMT) using a duplex scanner with a 
linear array transducer. Both right and left carotids were 
measured and presence of plaque was defined as ≥100% 
increase over background in any arterial segment [32].  
 
Serum samples were obtained from 322 population controls 
and 287 of these samples were individually age and sex 
matched to 287 SLE patients for comparison of IgM levels. A 
majority of individuals were also matched for residential area. 
Control subjects were identified in the Swedish national 
population registry without influence of clinical history and 
invited to participate. The only exclusion criterion was a 
diagnosis of SLE. All study participants were examined by a 
rheumatologist at the Karolinska University Hospital and 
medical records were reviewed. Validation assays also 
included 597 cryopreserved population control serum samples 
with known HLA-DRB1 alleles collected within the 
Epidemiological Investigation of Rheumatoid Arthritis (EIRA) 
study [33]. The local ethic committee at Karolinska University 
Hospital approved the study and all the experiments were 
performed according to good clinical practice and good 
laboratory practice. All study subjects gave written informed 
consent to participate. 
 
2.2 Antibody measurements 
Total IgM and total IgG levels were measured at the 
Karolinska University Hospital clinical laboratory by standard 
nephelometry. Antibodies to specific nuclear antigens (dsDNA, 
SSA/Ro52, SSA/Ro60, SSB/La, Sm, RNP) and 
antiphospholipid IgG, IgA and IgM (cardiolipin and β2-
glycoprotein-I) were analyzed by multiplexed bead technology 
(Luminex) using BioPlex 2200 system (Bio-Rad, Hercules) 
according to the specifications of the manufacturer. Analysis of 
IgM rheumatoid factor (RF) was performed on a Phadia 
ImmunoCap 250 instrument according to the manufacturer’s 
instructions. LA was determined using a modified Dilute 
Russell Viper Venom method (Biopool) using Bioclot lupus 
anticoagulant. 
 
Serum levels of natural antibodies to malondialdehyde (MDA)-
modified protein adducts or phosphorylcholine (PC) were 
measured by sandwich ELISA using previously described 
methods [25, 26]. High-binding half-area ELISA plates 
(Corning) were coated with PC6-bovine serum albumin (PC-
BSA, Biosearch Technologies), pneumococcal cell wall 
polysaccharide CWPS (CWPS, Statens Serum Institut), or 
MDA-modified BSA, (MDA-BSA, Academy Biomedical) at 3 
μg/ml in PBS and blocked with 3% BSA in PBS. Samples 
were analyzed at 1:200 and 1:1000 dilution. Binding was 
detected with HRP conjugated mouse anti-hIgM (µ-chain 
specific, Southern Biotech) followed by TMB substrate 
development. Absorbance was normalized to a standard curve 
of a positive reference sample which was included in all assays 
and quantitative reactivities were presented as Relative 
Units/ml (RU/ml). 
 
2.3 HLA-DRB1 profiling 
Low resolution HLA-DRB1 genotyping was performed by 
sequence-specific primer PCR as previously described [34]. 
The following HLA-DRB1 allelic groups were detected by this 
method: DRB1*01, DRB1*03, DRB1*04, DRB1*07, 
DRB1*08, DRB1*09, DRB1*10, DRB1*11, DRB1*12, 
DRB1*13, DRB1*14, DRB1*15 and DRB1*16, and were used 
for statistical evaluation with dominant model. 
 
2.4 Statistical analysis 
The distribution of antibodies, demographic parameters, and 
biomarkers were compared between different groups with two-
sided Mann-Whitney or Kruskal-Wallis test, as appropriate. 
Frequency distributions were compared with Fisher’s exact 
test. Non-parametric Spearman correlation was used to analyze 
associations between variables. Logistic regression models 
were used for multivariate analysis. A p-value of less than 0.05 
was considered significant. Analysis was performed using 
Prism 6 (Graphpad Software Inc), JMP 13 (SAS Institute Inc) 
and Review Manager 5.3 (Copenhagen: The Nordic Cochrane 
Centre, The Cochrane Collaboration, 2014). 
 
3. Results  
3.1 The frequency of depressed IgM is higher in SLE patients 
than in matched controls 
We initiated our studies by investigating whether natural IgM 
levels were altered in SLE patients compared to unaffected 
population controls. Two different classes of natural IgM 
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antibody specificities were studied, anti-PC and anti-MDA 
modified protein epitopes. While these are distinct types of 
oxidation-associated epitopes, specific anti-PC antibodies are 
cross-reactive with PC-epitopes present both in lipids and 
bacterial polysaccharide. In our studies, we therefore measured 
PC-reactivity with two different assays; using the small PC 
headgroup conjugated to a carrier protein (PC-BSA), or 
purified cell wall polysaccharide (CWPS).  
 
Our results show that average serum total IgM levels were 
higher in SLE patients compared to age- and gender- matched 
population controls, although the differences were very small, 
and the median value was lower in the SLE patients (SLE vs 
controls: mean±SD: 1.276±1.1 vs 1.265±0.71 mg/ml; median: 
0.96 vs 1.00 mg/ml, Table 2, Figure 1). Similarly, the average 
level of natural IgM binding to oxidation-associated MDA-
modifications was higher in SLE patients than in controls, 
while the median value was lower. In contrast, the levels of 
natural IgM anti-PC were lower overall in the SLE cohort 
compared to age- and gender- matched controls. Indeed, by 
both independent assays, which measured levels of IgM 
reactive with PC-conjugate or with CWPS, there were similar 
findings (Table 2, p=0.05 and p<0.0001). Notably, IgM anti-
PC-BSA and IgM anti-CWPS showed a strong direct 
correlation (p<0.0001, R=0.85, Supplemental Figure 1). 
Importantly, both from analysis for total IgM, as well as for 
anti-PC-BSA, anti-CWPS, and anti-MDA antibodies, there 
were more SLE patients with depressed IgM levels compared 
to the controls (Table 2). These patterns were not solely a 
reflection of total IgM levels, and highlight the heterogeneity 
of the SLE population.  
 
In our studies, we defined depressed specific IgM and total 
IgM in the SLE patients by a cutoff at the 25th percentile of the 
population controls and high IgG by a cutoff at the 75th 
percentile of the population controls. For total IgM, all tested 
individuals had detectable levels of IgM, and most of the SLE 
patients with low IgM were still within the normal range 
(>0.46mg/ml), based on the reported 2.5th percentile a study of 
the general population (Mean: 1.47± 0.84 mg/ml) [35]. In fact, 
only a small proportion, 13.6% of the SLE compared to 3% of 
the unaffected controls (of 322 subjects tested), had subnormal 
IgM levels. For IgG, mean levels of total IgG levels were 
significantly elevated in SLE patients (p<0.0001), and 60% 
had high IgG levels, over the 75% population control cutoff.  
 
We found significant direct correlations between each of the 
specific natural IgM antibody levels and total IgM (p<0.0001, 
Supplemental Figure 1), which confirmed findings in a 
previous report [26]. Notably, there were significant but 
modest inverse correlations of IgM anti-PC-BSA, anti-CWPS 
and anti-MDA with age (p=0.0006, R=-0.16; p<0.0001, R=-
0.25; p=0.0007, R=-0.17, respectively) (Supplemental Figure 
2). IgM anti-MDA demonstrated a weak positive association 
with disease activity by SLEDAI [30], while IgM anti-PC-BSA 
and IgM anti-CWPS correlated inversely with organ damage 
by SLICC [31] (Supplemental Table 1). The IgM levels did not 
correlate with current glucocorticoid treatment dose 
(Supplemental Table 2). As SLE is a female predominant 
disease, it may be important to note that total IgM levels and 
IgM anti-MDA were both significantly lower in men than 
women, among both SLE patients and unaffected population 
controls (controls: p=0.03 and p=0.03, respectively; SLE: 
p=0.04 and p=0.03, respectively). IgM anti-PC levels were also 
lower in the male SLE patients compared to female patients 
(p=0.03, Supplemental Table 3, Supplemental Figure 3). IgM 
anti-PC levels were in addition analyzed in a second 
independent population control cohort with a different 
demographic distribution (i.e., 27% males). Here, we 
confirmed that IgM anti-PC levels are significantly lower in 
male than in female adults (average 23% lower levels, 
p=0.0002) (Supplemental Figure 4). Yet, stratifying the 
patients based on sex did not markedly change the correlation 
between IgM levels in SLE patients compared to controls 
(Supplemental Table 4).  
 
3.2 IgM levels are primarily decreased in SLE patients with 
an IgG anti-Ro/La autoreactivity profile 
We next investigated whether natural IgM levels varied 
between different SLE subsets based on autoantibody profiles. 
Patients were characterized as having an APS-profile (with 
anti-CL/b2GPI) or a SS-profile (with IgG anti-Ro/La) as 
defined in Table 1. The remainder were assigned to a third 
group, SLE with other autoantibodies. Patients in this group 
often displayed anti-Sm/RNP autoantibodies. Indeed, these 
three subgroups were generally mutually exclusive, and only a 
few patients had either overlapping profiles or the data were 
insufficient for assignment. These three SLE patient subsets 
did not differ regarding mean age or disease activity (Table 3). 
However, the APS-profile subset had more anti-dsDNA 
positive patients than the SS-profile group (50% vs 28%, 
p=0.005).   
 
Among the most striking characteristics for the patient subset 
with the SS autoantibody profile were the significantly lower 
total serum IgM levels, as well as low IgM anti-PC-BSA, IgM 
anti-CWPS and IgM anti-MDA levels (Table 3, Figure 1). In 
contrast, patients with the APS autoantibody profile displayed 
higher mean levels of total IgM and IgM anti-MDA compared 
to controls, although these differences were not statistically 
significant. In the third SLE group (SLE with other 
autoantibodies) we also observed significant depression of 
some of the IgM measurements, although these associations 
were not as strong as for the SS subgroup. Total IgM seems an 
important component driving these correlations. However, in 
SS-profile SLE patients, IgM anti-PC-BSA and IgM anti-
CWPS levels were still significantly lower after normalizing 
for total IgM levels (i.e., IgM anti-PC-BSA/total IgM; IgM 
anti-CWPS/total IgM), whilst IgM anti-MDA/total IgM was 
not significantly different (Supplemental Table 5, 
Supplemental Figure 5). This may suggest that certain IgM 
specificities are more affected than others by the patients 
autoreactivity profile, and it also emphasizes that there are 
inherent differences between IgM anti-PC and IgM anti-MDA 
expression patterns. When dichotomizing the cohort base on 
only one autoantibody test, lower associated levels of IgM 
were observed based on anti-Ro60 positivity than anti-Ro52 
positivity, although not as remarkable as when using the 
autoantibody profiling strategy (data not shown). Hence, IgG 
anti-Ro60 positivity may be the stronger driver for low IgM in 
the SS-profile. No significant differences between IgM levels 
were observed after dichotomization of SLE patients according 
to their IgG anti-dsDNA status (Supplemental Figure 6) and 
the depressed IgM levels in the SS group were observed 
independently on anti-dsDNA status (data not shown). We also 
confirmed previous findings that IgM anti-PC levels are not 
affected by lupus nephritis [25], while the total IgM levels 
were lower in patients with a history of renal disease 
(Supplemental Table 6). Moreover, not all types of IgM 
specificities were equally depressed in the SS subgroup. In 
fact, levels of disease-associated rheumatoid factor IgM (RF 
IgM) were significantly elevated in the SS-profile group, 
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which may reflect the effects of a specific immune stimulation 
in this subset (Supplemental Figure 7, Supplemental Table 7). 
Similarly, while there was generally a direct correlation 
between in RF IgM and other IgM levels when all SLE patients 
were analyzed (Supplemental Figure 7), the few patients with 
high RF titers all had relatively low specific natural IgM levels 
and total IgM. These findings also confirmed that our assays 
were without technical bias caused by the presence of 
rheumatoid factors. Taken together, depressed IgM levels were 
primarily associated with the subgroup of SLE patients with SS 
autoantibody profile.  
 
To understand whether there were relationships between 
patients based on conserved patterns of (auto)antibody 
expression, we performed unsupervised hierarchical cluster 
analysis (using Cluster 3.0), (Figure 2). Our findings 
demonstrated that depressed IgM levels (i.e., both total IgM 
and specific natural IgM), enabled visualization of more 
general effects on heterogeneity of lupus antibody expression 
patterns. These analyses independently confirmed that low IgM 
levels were commonly found in the subgroup of SLE patients 
with anti-Ro/La IgG autoantibodies. In the cluster analysis, 
specific variations in HLA-DRB1 allelic expression also 
contributed to the discontinuous variations represented as 
different IgG autoantibody defined patient subgroups. Indeed, 
the three patient subsets displayed differences in the 
distribution of the HLA-DRB1 alleles, as the APS-profile 
group displayed a higher frequency of HLA-DRB1*04 
(p=0.002), while the SS-profile was enriched for HLA-
DRB1*03 (p<0.0001). The remaining patients, that included 
many subjects with anti-Sm/RNP IgG autoantibodies, more 
commonly had HLA-DRB1*15 alleles (p=0.0005) as well as 
HLA-DRB1*03 (p=0.001) alleles compared to the control 
group (Table 3). To a large extent, these findings confirm 
previously reported HLA-DRB1-autoantibody associations in 
SLE [34, 36, 37]. 
 
3.3 Low IgM levels may be associated with HLA-DRB1*03 
alleles 
As we observed strong HLA associations with IgG 
autoantibody profiles, and considering that the anti-Ro/La 
subgroup had both lower IgM and was significantly enriched 
for HLA-DRB1*03, it was not unexpected that there was also a 
significant association between low IgM and HLA DRB1*03. 
Indeed, SLE patients carrying a HLA-DRB1*03 allele had 
lower total IgM (p=0.05), IgM anti-PC-BSA (p=0.02), and 
IgM anti-MDA (p=0.05), as well as a trend towards lower IgM 
anti-CWPS (p=0.07) (Table 4, Figure 3). More surprisingly, 
we also found lower IgM levels in the HLA-DRB1*03 positive 
population controls, which were statistically significant for 
total IgM levels (p=0.03) and IgM anti-PC-BSA levels 
(p=0.04) (Table 4, Figure 3). These same associations were 
strengthened when both SLE and controls were combined in a 
meta-analysis, which revealed that HLA-DRB1*03 positive 
individuals had lower total IgM (p=0.007), IgM anti-PC-BSA 
(p=0.002), IgM anti-CWPS (p=0.007), and IgM anti-MDA 
levels (p=0.02) (Table 4, Figure 3). Similarly, in the groups 
with HLA-DRB1*03 positivity, the frequency of individuals 
with low IgM levels was also significantly higher (Table 4, 
Supplemental Figure 8). In addition, the control group showed 
trends towards allele copy dose-dependency as individuals 
homozygous for HLA-DRB1*03 displayed lower IgM levels 
seen in heterozygous, or null individual, with a significant 
difference for total IgM and IgM anti-CWPS levels in the 
HLA-DRB1*03 (-/-) group (p=0.03, p=0.04, respectively) 
(Supplemental Figure 9, Supplemental Table 8). Yet, when 
analyzing IgM anti-PC levels in a second independent 
population control cohort we did not find statistically 
significant differences in IgM levels between DRB1*03 
negative, heterozygous, and homozygous individuals, although 
the numeric trends remained consistent (Supplemental Figure 
10).  
  
By contrast, in these analyses there were no correlations 
between HLA-DRB1*03 and total IgG levels, in SLE or 
control groups (Table 4). We also investigated other HLA-
DRB1 variants, and in the meta-analysis that combined results 
from SLE patients and controls we documented significantly 
higher IgM anti-PC levels in individuals with HLA-DRB1*04 
positivity (p=0.009, Supplemental Table 9). In addition, the 
SLE patients with HLA-DRB1*15 had somewhat lower total 
IgG levels (p=0.05) but there was no association with levels of 
IgM (Supplemental Table 10).  
 
In multivariate logistic regression analysis, IgM levels 
remained significant independent variables when adjusting for 
DBR1*03, DRB1*04, DRB1*15, sex, age, and RF IgM 
positivity in models for determining if the SLE patient had the 
APS-profile, the SS-profile, or neither (IgM anti-PC-BSA 
p=0.03, IgM anti-CWPS p=0.03, IgM anti-MDA p=0.0001, 
total IgM p=0.0005) (Supplemental Table 11). These data may 
indicate that differences in IgM levels are influenced by other 
immunobiological co-factors.  
 
3.4 Low IgM associated cardiovascular risk is different in 
SLE subgroups 
SLE patients are reported to have an increased risk of 
premature cardiovascular disease, compared to matched 
unaffected controls [38, 39], and this risk may be greater in the 
subgroup of SLE patients with anti-phospholipid antibodies, 
while the risk is lower in SLE with anti-Ro/La positivity [40]. 
In our analysis, we confirmed a higher odds ratio (OR) for a 
history of a vascular event, including both arterial and venous 
events, in the APS-profile group (OR=2.7 CI: [1.6-4.4] 
p=0.0003), and a significantly lower OR for vascular events in 
the SS-profile group (OR=0.46 CI: [0.24-0.87] p=0.01), 
compared with the overall frequency in SLE patients (Table 5).  
 
When analyzing the complete SLE cohort, we observed an 
overall association for the presence of atherosclerotic carotid 
plaque with low IgM anti-PC (Table 5). SLE patients with low 
IgM anti-PC-BSA had an OR of 2.2 CI:[1.2-4.0] of having 
detectable carotid plaques by ultrasound (p=0.02) and patients 
with low IgM anti-CWPS similarly had an OR of 3.5 CI:[1.9-
6.5] in association to plaque (p<0.0001). Importantly, even 
after adjusting for age and sex, the frequency of low IgM anti-
CWPS in association to plaque remained significant (p=0.005). 
Notably, the association between low IgM anti-PC and 
cardiovascular disease was relatively moderate in this study 
compared to other cohorts [25, 26]. 
 
Vascular events were significantly more prevalent in the APS-
profile subgroup (48% compared to 23% in the total SLE 
cohort, p=0.0003), and were not influenced by depressed IgM 
anti-PC levels. In contrast, there was a significantly higher 
frequency of vascular events with low IgM in the “other 
autoAbs” group (low IgM anti-PC-BSA, OR 2.5, p=0.04). 
Similarly, there was no correlation between low IgM anti-PC 
and plaques in the APS-profile, while the frequency of 
atherosclerotic plaques in with low IgM anti-CWPS reactivity 
were significantly more prevalent in both the SS-profile group 
and the “other Abs group” (low IgM anti-CWPS p=0.0003 and 
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p=0.002) (Table 5). Results from the PC-BSA based assay, 
appeared to detect a higher frequency of patients with carotid 
plaques with low IgM anti-PC in the SS-profile SLE subgroup 
(28% vs 5%, OR=7.2, CI:[1.5-36], p=0.01) (Table 5). 
Consequently, while plaques are less common in the SS group, 
low IgM anti-PC levels may have a stronger impact on the 
atherosclerosis risk in this group. Furthermore, logistic 
regression analysis with both the autoantibody profile, sex, 
age, and low IgM levels, demonstrated that either low IgM 
anti-CWPS (p=0.003) or low IgM anti-PC-BSA (p=0.02) were 
significantly associated with presence of plaque, while total 
IgM and IgM anti-MDA were not (Supplemental Table 12).  
 
Cumulatively, our investigations have demonstrated that the 
immunologic heterogeneity among SLE patients is in part 
intertwined with low circulating levels of IgM, which may 
have differential effects on disease manifestations in individual 
SLE patients.  
 
4. Discussion 
Our study evaluated the expression levels in three lupus-
antibody defined SLE subgroups of IgM that recognize 
oxidation-associated epitopes, PC and MDA, which are 
common components of the natural antibody repertoire that is 
postulated to have protective homeostatic properties. We 
demonstrated that the frequency of individuals with depressed 
levels of total IgM, and of either of the tested oxidization-
associated IgM specificities, is more prevalent in SLE patients 
than in unaffected matched controls. Strikingly, we 
documented large differences in IgM levels between the three 
SLE subgroups, with dramatically lower IgM levels observed 
in patients with IgG anti-Ro/La autoreactivity, compared to 
patients with antiphospholipid autoantibodies. However, the 
mechanisms responsible for these altered patterns of IgM 
expression in autoimmunity are essentially unknown. 
Furthermore, the higher probability of atherosclerotic 
cardiovascular disease associated with low IgM is primarily 
associated with the patients without antiphospholid antibodies. 
Our investigation therefore highlights the heterogeneity of SLE 
patients based on their autoantibody profiles, especially 
between anti-Ro/La versus anti-CL/b2GPI profiles.  
 
We have previously reported that anti-PC and anti-MDA 
recognize distinct epitopes and these antibodies display non-
overlapping binding specificities [25, 26, 41]. Especially IgG 
anti-PC and anti-MDA have very different expression pattern 
in autoimmune patients and in rheumatoid arthritis IgG anti-
MDA levels are associated with higher disease activity and 
potentially pathogenic properties [42]. IgM anti-MDA is a 
natural antibody specificity that is prevalent at birth but may 
also arise in part in response to inflammatory stimuli that are 
increased during autoimmune pathogenesis [25, 26, 41]. On the 
other hand, IgM anti-PC, are more prevalent in the circulation 
of healthy adults. However, anti-PC antibodies can also 
recognize determinants on the cell wall polysaccharide of all S. 
pneumonia strains and therefore their levels may be further 
induced in response to bacterial exposure. Murine studies have 
suggested that there are differences in PC-recognition 
dependent on the antigen, consequently leading to different 
classes of anti-PC antibodies [43]. To ensure completeness in 
our serologic surveys, we therefore decided to measure two 
different forms of phosphorylcholine, the PC headgroup 
conjugated to a carrier (PC-BSA) and the PC epitope in 
pneumococcal cell wall polysaccharide (CWPS). Patterns of 
reactivity to these two antigens were very similar, although not 
identical, and we conclude that there is, as expected, a large 
overlap between oxidized lipid- and polysaccharide-reactivity 
in humans. 
 
We speculate that certain IgM binding specificities may be 
inducible by increased oxidation, apoptotic cells, and overall 
burden of neo-antigens, while others may be more dependent 
on genetic predisposition. Moreover, the balance between 
expression and consumption of natural IgM is not understood. 
In this report, we use the terminology “depressed IgM” and 
postulate that IgM levels are affected by active processes, yet 
longitudinal studies are needed to reveal if low IgM precedes 
lupus or is a consequence of the disease process. IgM generally 
have short circulating half-lives of at most a few days, and 
unlike IgG there is no mechanism for IgM re-cycling. As a 
consequence, antigen recognition and binding likely leads to 
consumption and clearance. In studies that integrated the 
sorting of PC-specific peripheral B cells, serum levels of IgM 
anti-PC antibodies were shown to be proportional to the 
frequency of PC reactive-circulating B cells [44]. Moreover, a 
cohort of SLE patients was shown to have lower serum total 
IgM compared to healthy controls, with higher proportions of 
polyreactive IgM [45]. We therefore postulate that in some 
patient groups, there are increased levels of certain specificities 
of autoreactive antibodies in the IgM repertoire.  
 
The observed differences in the levels of IgM to oxidation-
associated determinants were relatively modest in the 
comparisons of the complete SLE cohort with the matched 
population controls. Importantly, our studies also showed that 
IgM levels are generally higher in women than men, and lower 
in older individuals, which further highlights the importance of 
well-matched control cohorts. The inverse correlation of 
natural IgM levels with age may reflect changes in the natural 
antibody repertoire, and there are distinct phases of immune-
development occurring in the perinatal period, as well as later 
age-associated changes, of innate-like B cells [46]. Although 
also previously reported, the factors responsible for higher 
levels of certain natural IgM binding specificities in women 
remain obscure [27, 47, 48].  
 
We hypothesize that the dramatic differences in IgM levels in 
the SLE subgroups reflects variations in the underlying 
immunopathology in these distinctly different patients. Of the 
several possible explanations for low natural IgM, it may 
reflect consumption of IgM that follows immune complex 
formation with the increased burden of apoptotic cell 
breakdown products, and/or a disease-associated shift in the B-
cell repertoire away from IgM secretion and towards IgG 
production. Primary Sjögren’s patients are known to have very 
high circulating IgG anti-Ro/La autoantibody levels and 
elevated total IgG [49]. Indeed, in our study the patients with 
SS-profile had higher total IgG levels, although there was no 
direct correlation between IgM and IgG levels. Alternatively, a 
generalized pro-inflammatory milieu may directly affect the B 
cells themselves, as activated leukocytes are a source of B-cell 
survival factors that interfere with immune tolerance deletion 
mechanisms as well as enhanced differentiation and 
autoantibody expression. Stimulation of innate immune 
receptors, such as TLR7/9, can besides promoting IgG class-
switch, also induce high level IgM production [50]. Hence, 
TLR ligands and/or cytokine expression likely differentially 
affecting the different SLE subgroups. Furthermore, a recent 
report demonstrates depressed IgM levels also in female first-
degree relatives to SLE patients, further suggesting a role of 
genetic, epigenetic, or shared environmental factors [51]. It is 
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also important to acknowledge that the ethnicity distribution in 
study cohorts may influence the underlying genetics and 
autoantibody profiles, and it is possible that the European SLE 
population presented here may differ with regard to antibody 
profile and subgroups as compared to other SLE cohorts with 
patients of different ethnicities. Consequently, IgM levels may 
be dependent on genetic influences, predisposing for 
production of certain types of protective (or pathogenic) 
autoantibodies.  
 
In general, MHC allelic variation is the strongest genetic 
contribution to SLE susceptibility, and especially HLA-
DRB1*15 and HLA-DRB1*03 that have documented an 
overall association with SLE diagnosis [52, 53]. In particular, 
HLA-DRB1*03 appears to predispose to development of 
secondary Sjögren’s syndrome and anti-Ro/La positivity [36, 
37]. Similarly, HLA-DRB1*04 and HLA-DRB1*13 are 
reported to correlate with increased risk for antiphospholipid 
IgG positivity and associated vascular events in SLE [34]. In 
the current study, we found that a high proportion of the 
subgroup with APS-profile bore HLA-DRB*04, while the SS-
profile group displayed high representation of HLA-DRB1*03. 
We also found that IgM levels were generally lower in the SS 
group, and in an individual DRB1*03 inheritance also 
correlated with decreased serum IgM levels. Unexpectedly, 
this correlation was also documented in the population controls 
that were negative for anti-Ro/La IgG. The results were 
confirmed in our meta-analysis, which combined the SLE 
cohort and the population controls. We hypothesize that HLA-
DRB1 alleles may affect serum total IgM levels, which we 
found are preferentially associated with different IgG 
autoantibody-defined SLE subsets, although other factors are 
also likely contributory. While the correlation of specific HLA 
alleles with IgG autoantibodies may be explained by 
preferential autoantigen presentation and T cell activation, a 
correlation between natural IgM with HLA has not been 
previously investigated.  
 
Our data propose that IgM levels may be partly genetically 
determined. Natural antibodies are generally defined as 
spontaneously secreted T-cell independent responses, which 
primarily arise from innate-like B-1 cells [13]. Yet, it has 
recently been reported that anti-PC and anti-MDA, considered 
prototypic types of natural IgM antibodies, can at least to some 
extent, be T-cell dependent [54]. Indeed, innate-like B cells can 
also serve as antigen-presenting cells for T cells [55]. 
Importantly, IgM anti-PC, which can protect from 
disseminated pneumococcal infection, are impaired in mice 
transgenic for HLA-DRB1*03 [56]. However, the biochemical 
and immunological biases for these impaired post-immune 
responses remain unexplained. 
 
IgG anti-Ro autoantibodies are associated with neonatal lupus 
and congenital heart block in a subset of pregnancies in women 
with anti-Ro autoimmunity [57, 58]. Our previous studies of 
newborn babies in a neonatal lupus cohort showed that IgG 
anti-Ro autoreactivity in the mother can affect the natural IgM 
levels in the baby [41]. In fact, if the mother carried IgG anti-
Ro autoantibodies, we observed that the baby had higher levels 
of total IgM but decreased levels of natural IgM anti-MDA. 
Notably, these findings were neither dependent of symptoms of 
autoimmune disease in the mother nor the child [41]. This 
association may suggest a change in the B cell repertoire 
leading to reduced production of some IgM and higher 
expression of others. This may be due to anti-Ro IgG crossing 
the placenta and forming stimulatory immune complexes in the 
fetal circulation, or, alternatively, fetal B cells may be 
stimulated by other pro-inflammatory molecules from the 
mother. Yet, it may also reflect shared inherited factors, that 
later in life contribute to an increased risk of developing IgG 
anti-Ro/La autoreactivity. Consequently, the low IgM levels in 
the SS-profile group observed in the current studies could have 
first arisen during the perinatal period. Furthermore, even 
though murine studies have convincingly demonstrated that 
autoimmune disease is significantly augmented by lack of 
circulating polymeric IgM [59], other studies have shown that 
under certain circumstances natural IgM can also induce an 
interferon signature [59]. Hence, we do not know how 
differences in the natural IgM may affect the development of 
autoantibodies in humans.  
 
Many reports have shown that low natural IgM to PC, and to 
certain MDA-modified epitopes, are associated with higher 
risk of atherosclerosis and cardiovascular events in SLE [21, 
25, 26, 28, 60]. Here we report the lowest IgM anti-PC levels 
in the anti-Ro/La patient subgroup and higher in the APS-
profile group despite the fact that the latter bear a higher risk of 
vascular events [40]. The increased occurrence of 
cardiovascular events in SLE is believed to arise from the 
contributions of different underlying pathologic influences, 
including antiphospholipid antibody associated thrombosis, 
impaired renal function, myocardial perfusion abnormalities, 
endothelial changes and accelerated atherosclerosis [61]. Low 
protective IgM anti-PC levels are more likely to contribute to 
processes responsible for vascular inflammation and 
atherosclerosis, which is consistent with our results. Moreover, 
it may be important to consider these differences when using 
low anti-PC as marker of cardiovascular risk. The results may 
be significantly influenced by the patient subgroup, and 
possibly genetic, immunological, and sex differences between 
patients with different autoantibody predominance.  
 
In summary, our current findings demonstrate that depressed 
IgM levels in SLE, both total and natural IgM, are common in 
the SS-profile subgroup of the SLE patients, which are also 
predominantly HLA-DRB1*03 positive individuals. In 
contrast, SLE patients with an APS-profile had similar IgM 
levels as the controls. Whereas SLE is an extremely 
heterogeneous disease with patients that vary greatly by 
immunological profiles and clinical manifestations, and our 
new perspectives on depressed natural IgM levels provide an 
entirely new set of insights into the determinators of patient 
immunological and clinical diversity. This study is a further 
step towards clarifying the relationship between natural IgM 
and IgG autoreactivity. Yet, much remains to be learned about 
the protective role of IgM in relation to the early development 
of autoimmune disease. Similarly, we still need to increase our 
knowledge about how genetic and environmental factors may 
shape the B cell repertoire and contribute to predisposition to 
certain autoimmune manifestations. 
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Figure 1. IgM levels in different SLE subgroups  
Immunoglobulin levels were compared in 287 individually sex and age matched SLE patients and 287 
population controls (A, C, E, G, I). IgM and IgG levels were also compared in different SLE patient subgroups 
based on their IgG autoantibody profiles (B, D, F, H, J, see Table 1 for subgroup criteria). Briefly, 318 
population controls were compared to 78 SLE patients with antiphospholipid (APS) autoantibody profile (with 
IgG anti-CL/b2GPI), 98 patients with Sjögren’s syndrome (SS) autoantibody profile (with IgG anti-Ro/La) and 
the remaining patient group consisting of 160 SLE patients with other autoantibodies (Other Abs). Specific 
natural IgM levels, IgM anti-PC-BSA, IgM anti-CWPS and IgM anti-malondialdehyde (MDA) modified protein, 
were measured by ELISA and quantitative reactivates were depicted as Relative Units (RU)/ml. P-values were 
derived from Mann-Whitney or Kruskal-Wallis test, adjusted for multiple comparisons. 
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Figure 2. Low IgM levels contribute to SLE heterogeneity   
Visualization of heterogeneity of SLE patients with regards to autoantibody reactivity, HLA-DRB1 positivity, 
and low IgM levels, using hierarchical uncentered cluster analysis of 336 SLE patients. All included variables 
were dichotomous (yes or no) and the data vas clustered both based on patient (y-axis) and variable (x-axis). The 
analysis shows for example that APS autoantibody positivity cluster with HLA-DRB1*04 and SS autoantibody 
positivity cluster with HLA-DRB1*03. The SLE patients that were categorized as having an SS-profile (yellow) 
or APS-profile (purple) primarily cluster together in separate clusters and the low IgM levels contribute to the 
patient heterogeneity and subgroup clustering. Cluster analysis was performed using Cluster 3.0 and 
visualization using Java Treeview.   
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Figure 3. Individuals with HLA-DRB1*03 genotype have lower levels of circulating IgM independent of 
autoreactivity  
The left panels show immunoglobulin levels in 249 HLA-DRB1*03 negative population controls compared to 
68 HLA-DRB1*03 positive individuals, and 174 HLA-DRB1*03 negative SLE patients compared to 150 HLA-
DRB1*03 positive SLE patients. The DRB1*03 positive groups included individuals that were both 
heterozygous and homozygous for the allele. The presented p-values were calculated using Mann-Whitney 
analysis. The right panels show the meta-analysis combining controls and the SLE groups, and calculating the 
difference in means using Inverse Variance method with fixed effect. Forest plots visualizing the mean 
differences (DRB1*03 positive – DRB1*03 negative) in the different cohorts and the combined data are 
presented (adapted from Review Manager 5.3 outputs). 
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Table 1. Division of SLE patients into subgroups based on IgG autoantibody profiles 
SLE with SS-profile 
(N=78) 
SLE with APS-profile 
(N=98) 
SLE with other autoAbs# 
(N=160) 
IgG anti-Ro52/Ro60/La ³2 positive tests IgG anti-CL/b2GPI = 2 positive tests Remaining SLE 
LA negative and/or Lupus Anticoagulant positive test IgG Anti-Ro52/Ro60/La £1 positive test 
 and/or IgM/IgA anti-CL/b2GPI ³2 positive tests LA negative 
 
# This group includes patients with anti-RNP/Sm autoantibodies but also subjects who were both ANA-negative/APS-negative, and the ANA-positive SLE patients with only 
IgG anti-dsDNA. 
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Table 2. IgM levels in SLE patients compared to matched population controls  
 
 Controls * 
(N=287) 
SLE  
(N=287) 
 
 Frequency/ 
Mean 
Frequency/ 
Mean 
p-value** 
Age (years; Mean±SD) 47.9±14.7 47.7±14.7 NS (0.87) 
Female (% n/N)# 92% (265/287) 92% (265/287) NS (1) 
Antibody levels    
Total IgM (mg/ml; Mean±SD [median]) 1.265±0.70 [1.00] 1.276±1.1 [0.96] 0.02 
Low total IgM (<0.8mg/ml)§ 25% (71/283) 38% (109/283) 0.0008 
a-PC-BSA IgM (RU/ml; Mean±SD [median]) 48.1±43.1 [33.3] 43.4±46.6 [24.4] 0.05 
Low a-PC-BSA IgM (<14 RU/ml)§ 26% (75/287) 29% (84/287) NS (0.3) 
a-CWPS IgM (RU/ml; Mean±SD [median]) 
[median])) 
59.7±56.4 [36.2] 49.5±61.4 [26.8] <0.0001 
Low a-CWPS IgM (<21 RU/ml)§ 25% (73/287) 40% (115/287) 0.0003 
a-MDA IgM (RU/ml; Mean±SD [median]) 41.8±62 [31.0] 46.2±76 [25.4] 0.009 
Low a-MDA IgM (<22 RU/ml) § 25% (74/287) 41% (118/287) 0.0001 
Total IgG (mg/ml; Mean±SD [median]) 10.9±2.0 [10.9] 14.1±5.2 [14.3] <0.0001 
High total IgG (>12mg/ml)§§ 25% (70/283) 60% (170/283) <0.0001 
 
n= number of patients with a positive test 
N= number of patients with measurement information 
SD= standard deviation 
*Population controls, age and sex matched to SLE patients.  
n= 287 for anti-PC and anti-MDA levels; n=283 for total IgM and total IgG levels 
** p-values derived from Mann-Whitney test or Fisher’s exact test 
§ Cutoff based on lowest quartile (25%) of all available controls N=322 (anti-PC/MDA) N=318 (total IgM) 
§§ Cutoff based on highest quartile (75%) of all available controls N=318  
Patients ever receiving Rituximab treatment were excluded  
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Table 3. Patient characteristics and IgM levels in different SLE subgroups 
 
 Controls  
(N=318) 
SLE with APS-profile 
(N=78) 
SLE with SS-profile 
(N=98) 
SLE with other autoAbs 
(N=160) 
APS vs SS 
profile 
 Frequency/ 
Mean 
Frequency/ 
Mean 
p-value* Frequency/ 
Mean 
p-value* Frequency/ 
Mean 
p-value* p-value** 
Patient characteristics         
Age (years, Mean ±SD) 47.4±15 49.5±15 NS (0.89) 48.7±14.4 NS (0.99) 45.4±16  NS (0.45) NS (0.73) 
Female  92% (292/318) 89% (69/78) NS (0.36) 85% (83/98) 0.05 94% (150/160) NS (0.58) NS (0.51) 
SLEDAI ³6 (%, n/N) N/A 39% (29/75) N/A 29% (28/97) N/A 27% (41/150) N/A NS (0.19) 
APS syndrome# % N/A 51% (39/77) N/A 3% (3/96) N/A 4% (7/160) N/A <0.0001 
Sjögren’s syndrome# %  N/A 14% (11/78) N/A 41% (40/97) N/A 19% (31/160) N/A <0.0001 
HLA DRB1 *03 pos (%, n/N) 21.4% (67/313) 26% (16/62) NS (0.50) 79% (67/85) <0.0001 37% (49/134) 0.001 <0.0001 
HLA DRB1 *04 pos (%, n/N) 33.2% (107/313) 57% (35/62) 0.002 18% (15/85) 0.003 27% (36/134) NS (0.15) <0.0001 
HLA DRB1 *15 pos (%, n/N) 29.7% (93/313) 31% (19/62) NS (0.88) 27% (23/85) NS (0.68) 47% (63/134) 0.0005 NS (0.71) 
SLE autoantibodies         
Total IgG (mg/ml; Mean±SD) 10.9±2.1 14±5.1 <0.0001 16±6.6 <0.0001 13±4.7 <0.0001 0.005 
High total IgG (>12mg/ml) 27% (87/318) 55% (43/78) <0.0001 74% (72/98) <0.0001 54% (85/159) <0.0001 0.02 
a-dsDNA IgG pos (%, n/N)€ 1.4% (4/278) 50% (39/78) <0.0001 28% (27/98) <0.0001 38% (61/160) <0.0001 0.005 
a-CL IgG pos (%, n/N) 0% (0/275) 76% (50/66) <0.0001 0% (0/82) NS (1) 0% (0/158) NS (1) <0.0001 
a-b2GPI IgG pos (%, n/N) 0% (0/273) 74% (49/66) <0.0001 0% (0/82) NS (1) 3% (4/158) 0.02 <0.0001 
a-Ro52/SSA IgG pos (%, n/N) 1.1% (3/274) 5% (4/78) 0.05 90% (88/98) <0.0001 3% (4/160) NS (0.43) <0.0001 
a-Ro60/SSA IgG pos (%, n/N) 1.8% (5/274) 13% (10/78) 0.0002 100% (98/98) <0.0001 18% (28/160) <0.0001 <0.0001 
a-La/SSB IgG pos (%, n/N) 2.9% (8/274) 3% (2/78) NS (1) 79% (77/98) <0.0001 2% (3/160) NS (0.75) <0.0001 
a-Sm IgG pos (%, n/N) 0.4% (1/274) 14% (11/78) <0.0001 12% (12/98) <0.0001 25% (40/160) <0.0001 NS (0.82) 
a-RNPa IgG pos (%, n/N) 3.2% (9/274) 17% (13/78) 0.0001 15% (15/98) 0.0001 31% (50/160) <0.0001 NS (0.84) 
RF IgM pos (%, n/N) 4.9% (14/283) 10% (6/58) NS (0.12) 51% (41/81) <0.0001 19% (25/132) <0.0001 <0.0001 
RF IgG pos (%, n/N) 3.8% (10/261) 18% (10/57) 0.0007 29% (21/72) <0.0001 10% (12/120) 0.03 NS (0.15) 
IgM natural antibodies         
Total IgM (mg/ml; Mean±SD) 1.26±0.68 1.6±1.7 NS (0.99) 0.97±0.58 <0.0001 1.27±1.1 NS (0.09) 0.0004 
Low total IgM (<0.8 mg/ml)§ 25% (79/318) 28% (22/78) NS (0.56) 45% (44/98) 0.0002 38% (60/159) 0.004 0.03 
a-PC-BSA IgM (RU/ml; Mean±SD) 48.5±43 54±54 NS (0.99) 28±32 <0.0001 46±45 NS (0.99) 0.0005 
Low a-PC-BSA IgM (<14 RU/ml)§ 25% (79/318) 24% (19/78) NS (1) 46% (45/98) 0.0001 23% (37/160 NS (0.74) 0.004 
a-CWPS IgM (RU/ml; Mean±SD) 60.7±57 61±80 NS (0.17) 32±35 <0.0001 50±54 0.009 0.02 
Low a-CWPS IgM (<21 RU/ml)§ 24% (77/318) 34% (27/78) NS (0.08) 47% (46/98) <0.0001 36% (57/160) 0.01 NS (0.12) 
a-MDA IgM (RU/ml; Mean±SD) 42±59 87±157 NS (0.08) 32±30 0.003 39±44 0.04 0.0001 
Low a-MDA IgM (<22 RU/ml)§ 25% (81/322) 23% (18/78) NS (0.77) 47%(46/98) <0.0001 39% (63/160) 0.002 0.002 
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n= number of patients with a positive test 
N= number of patients with measurement information 
SD= standard deviation 
# Fulfill clinical criteria for secondary Antiphospholipid syndrome (APS) by Miyakis [6] or Sjögren’s syndrome by the European/American consensus [9] 
* P-value compared to controls from Kruskal-Wallis test, adjusted for multiple comparisons, or Fisher’s exact test 
§ Cutoff based on lowest quartile (25th percentile) of all available controls N=322 (anti-PC/MDA) n=318 (total IgG/IgM) 
§§ Cutoff based on highest quartile (75th percentile) of all available controls N=318  
€ In the complete SLE cohort we observed 38% IgG anti-dsDNA positivity  
** P-values derived from Mann-Whitney test or Fisher’s exact test 
Patients that had received Rituximab treatment were excluded 
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Table 4. IgM levels are lower in individuals positive for HLA-DRB1*03 
 
§ Cutoff based on lowest quartile (25th percentile) of all available controls N=322 
§§ Cutoff based on highest quartile (75th percentile) of all available controls N=318  
# p-value from 2-sided Mann-Whitney test or Fisher’s exact test 
¶ p-value from Meta-analysis using Mantel-Haenszel method (for frequencies) for Inverse Variance method (for comparing means) with fixed effect. 
Patients ever receiving Rituximab treatment were excluded from the analysis.  
NS= Non-significant, CI= confidence interval, MD=Mean difference, OR= Odds ratio 
HLA-DRB1*03 positive patients, includes patients both heterozygous and homozygous for the allele. 
  
 Controls  SLE  Meta-analysis: Controls and SLE 
 DRB1*03 neg 
(n=249) 
DRB1*03 pos 
(n=68) 
 DRB1*03 neg 
(n=174) 
DRB1*03 pos 
(n=150) 
 DRB1*03 pos vs DRB1*03 neg 
 Frequency/ 
Mean±SD 
Frequency/ 
Mean±SD 
P-value# Frequency/ 
Mean±SD 
Frequency/ 
Mean±SD 
P-value# Mean difference/  
Odds Ratio, [95% CI] 
P-value	¶ 
Total IgM (mg/ml) 1.30±0.72 1.12±0.59 0.03 1.38±1.24 1.16±1.17 0.05 MD: -0.19 [-0.33, -0.05]  0.007 
Low Total IgM§ 23% (57/246) 33% (22/67) NS (0.11) 34% (60/174) 42% (63/150) NS (0.17) OR: 1.46 [1.02, 2.09] 0.04 
a-PC-BSA IgM (RU/ml) 50.5±44.0 40.7±39.8 0.04 48.2±50.3 35.7±38.3 0.02 MD: -11.32 [-18.56, -4.08] 0.002 
Low a-PC-BSA IgM§ 21% (53/249) 40% (27/68) 0.003 26% (45/174) 37% (55/150) 0.04 OR: 1.92 [1.33, 2.77] 0.0004 
a-CWPS IgM (RU/ml) 62.5±58.8 51.1±45.4 NS (0.14) 54.6±66.1 41.7±49.7 NS (0.07) MD: -12.14 [-21.04, -3.25] 0.007 
Low a-CWPS IgM§  22% (56/249) 32% (22/68) NS (0.11) 36% (63/174) 44%( 66/150) NS (0.17) OR: 1.47 [1.03, 2.10] 0.03 
a-MDA IgM (RU/ml) 43.7±66 34.1±24 NS (p=0.08) 52.0±93 40.0±80 0.05 MD: -10.13 [-18.95, -1.30] 0.02 
Low a-MDA IgM §  25% (62/249) 26% (18/68) NS (p=0.87) 37% (64/174) 48% (73/150) 0.03 OR: 1.42 [0.99, 2.02] NS (0.06) 
Total IgG (mg/ml) 10.8±2.1 11.1±2.2 NS (0.53) 13.8±5.2 14.2±5.4 NS (0.68) MD: 0.28 [-0.26, 0.81] NS (0.31) 
High total IgG§§ 24% (58/246) 30% (20/67) NS (0.34) 58% (101/174) 58% (87/150) NS (1) OR: 1.12 [0.78, 1.59] 
 
NS (0.55) 
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Table 5. Cardiovascular risk in association to low IgM anti-PC in different SLE subgroups 
 
 
*History of vascular events, includes both arterial and venous events 
** p-value by Fisher’s exact test for the subgroup compared to all SLE  
§ Cutoff based on lowest quartile (25th percentile) of all available controls n=322 
€ Presence of atherosclerotic plaque by carotid ultrasound intima media thickness measurements 
#p-value by Fisher’s exact test for low IgM levels compared to high IgM levels (above cutoff for low levels).  
OR: Odds ratio; CI: Confidence interval 
 
 All SLE   High IgM  
anti-PC-BSA  
>14 RU/ml§ 
Low IgM  
anti-PC-BSA  
≤14 RU/ml 
  High IgM 
anti-CWPS  
>16 RU/ml§ 
Low IgM 
anti-CWPS 
≤16 RU/ml 
  
 Frequency OR [95% CI] p-value** Frequency Frequency OR [95% CI] p-value# Frequency Frequency OR [95% CI] p-value# 
All SLE            
Plaque€ 21% (55/263)   16% (31/188) 31% (24/80) 2.2 [1.2-4.0] 0.02 12% (20/162) 33% (35/106) 3.5 [1.9-6.5] <0.0001 
Vascular events* 26% (98/380)   23% (61/263) 32% (37/117) 1.5 [0.94-2.5] NS (0.10) 23% (53/230) 30% (45/150) 1.4 [0-90-2.3] NS (0.15) 
            
SLE with APS-profile           
Plaque 25% (13/52) 1.3 [0.62-2.5] NS (0.58) 20% (8/39) 39% (5/13) 2.4 [0.62-9.5] NS (0.26) 24% 8/34 27% (5/18) 1.25 [0.34-4.6] NS (0.75) 
Vascular events 48% (36/75) 2.7 [1.6-4.4] 0.0003 47% (27/57) 50% (9/18) 1.1 [0.38-3.2] NS (1.0) 47% (23/49) 50%(13/26) 1.1 [0.4-2.9] 0.81 
            
SLE with SS-profile           
Plaque 16% (12/73) 0.74 [0.37-1.5] NS (0.51) 5% 2/38 28% (10/35) 7.2 [1.5-36] 0.01 3% (1/36) 30% (11/37) 14.8 [1.8-122] 0.003 
Vascular events 14% (13/94) 0.46 [0.24-0.87] 0.01 14% (7/51) 14% (6/43) 1.0 [0.31-3.3] NS (1.0) 12% (6/50) 16% (7/44) 1.39 [0.4-4.5] NS (0.77) 
            
SLE with other autoAbs            
Plaque 23% (28/123) 1.1 [0.67-1.9] NS (0.69) 19% (19/98) 36% (9/25) 2.3 [0.90-6.1] NS (0.11) 14% (11/80) 40% (17/43) 4.1 [1.7-9.9] 0.002 
Vascular events 22% (34/153) 0.82 [0.52-1.3] NS (0.44) 18% (21/116) 35% (13/37) 2.5 [1.1-5.6] 0.04 19% (18/97) 29% (16/56) 1.8 [0.81-3.8] NS (0.16) 
